
pmid: 23174361
Primary temporal bone tumors are rare. Suspicious lesions of the ear canal should be biopsied for diagnosis. Surgical resection to achieve negative margins is the mainstay of treatment. Small tumors can be treated with lateral temporal bone resection. Parotidectomy and neck dissection are added for disease extension and proper staging. Higher staged tumors generally require subtotal temporal bone resection or total temporal bone resection. Adjuvant postoperative radiotherapy has shown improved survival for some patients. Chemotherapy has an emerging role for advanced stage disease. Evaluation and management by a multidisciplinary team are the best approach for patients with these tumors.
Survival, Temporal Bone, Combined Modality Therapy, Magnetic Resonance Imaging, Skull Base Neoplasms, Neurosurgical Procedures, Facial Nerve, Postoperative Complications, Humans, Neck Dissection, Parotid Gland, Neoplasm Recurrence, Local, Tomography, X-Ray Computed
Survival, Temporal Bone, Combined Modality Therapy, Magnetic Resonance Imaging, Skull Base Neoplasms, Neurosurgical Procedures, Facial Nerve, Postoperative Complications, Humans, Neck Dissection, Parotid Gland, Neoplasm Recurrence, Local, Tomography, X-Ray Computed
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 61 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
